Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.36 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037281 | 1.00 | ADCY1 (0.39) | ADCY1KDM4EALDH1A1L3MBTL1HPGD | |
| SCHEMBL1082984 | 0.91 | KDM4E (0.39) | ADCY1KDM4EALDH1A1L3MBTL1HPGD | |
| SCHEMBL1082986 | 0.91 | KDM4E (0.39) | ADCY1KDM4EALDH1A1L3MBTL1HPGD | |
| SCHEMBL1033442 | 0.88 | ADCY1 (0.51) | ADCY1KDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL1033441 | 0.88 | ADCY1 (0.51) | ADCY1KDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL1035167 | 0.88 | ADCY1 (0.44) | ADCY1KDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL1035170 | 0.88 | ADCY1 (0.44) | ADCY1KDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL1033109 | 0.87 | KDM4E (0.43) | ADCY1KDM4EALDH1A1L3MBTL1GPR65 | |
| SCHEMBL1033111 | 0.87 | KDM4E (0.43) | ADCY1KDM4EALDH1A1L3MBTL1GPR65 | |
| SCHEMBL1035528 | 0.86 | KDM4E (0.48) | KDM4EALDH1A1L3MBTL1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053950-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER, INC. | 2011-03-03 | — | — | US | claimed |
| EP-2276734-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009127946-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | claimed |
| US-20110053950-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER, INC. | 2011-03-03 | — | — | US | disclosed |
| EP-2276734-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127946-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053950-A1 | 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, CNR2 | ADCY1 378/4885KDM4E 626/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.